To include your compound in the COVID-19 Resource Center, submit it here.

FDA accepts sBLA for Keytruda to treat primary mediastinal B cell lymphoma

Merck & Co. Inc. (NYSE:MRK) said FDA accepted for review an sBLA for Keytruda pembrolizumab (MK-3475) to

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE